Optus Pharmaceutical Shifts QLOSI Licensing Milestones to Sales-Based Payments

Bitget2026/10/22 06:56

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Optus Pharmaceutical's Oct. 22, 2026, correction replaced QLOSI's USD 9.77 million regulatory-approval milestone payment with sales-based payments.
Total milestone payments remain USD 12.22 million under the licensing agreement with Orasis Pharmaceuticals.
The Korean NDA submission payment falls to USD 2 million from USD 2.45 million.
Payments of USD 2 million and USD 8.22 million become due at cumulative net sales of USD 40 million and USD 80 million, respectively.
The NDA submission payment becomes 50% refundable, equivalent to USD 1 million, subject to contractual conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Optus Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261022900365), on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Optus Pharmaceutical Shifts QLOSI Licensing Milestones to Sales-Based Payments

You may also like

Crypto prices